KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EBT (2016 - 2025)

Idexx Laboratories (IDXX) has 17 years of EBT data on record, last reported at $307.0 million in Q4 2025.

  • For Q4 2025, EBT rose 19.73% year-over-year to $307.0 million; the TTM value through Dec 2025 reached $1.3 billion, up 19.31%, while the annual FY2025 figure was $1.3 billion, 19.31% up from the prior year.
  • EBT reached $307.0 million in Q4 2025 per IDXX's latest filing, down from $344.8 million in the prior quarter.
  • Across five years, EBT topped out at $362.4 million in Q2 2025 and bottomed at $171.1 million in Q2 2022.
  • Average EBT over 5 years is $262.9 million, with a median of $257.7 million recorded in 2024.
  • Peak YoY movement for EBT: skyrocketed 75.54% in 2021, then crashed 32.04% in 2022.
  • A 5-year view of EBT shows it stood at $191.9 million in 2021, then rose by 11.12% to $213.2 million in 2022, then rose by 12.41% to $239.7 million in 2023, then increased by 6.98% to $256.4 million in 2024, then increased by 19.73% to $307.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $307.0 million in Q4 2025, $344.8 million in Q3 2025, and $362.4 million in Q2 2025.